全部產業訊息

View More
UBI集團訊息
30112019
聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於多重抗藥性HIV感染病患之臨床試驗協議

NIH/NIAID將贊助UB-421應用於治療多重藥抗藥性(Multiple Drug Resistance，MDR)HIV感染之臨床試驗。

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於多重抗藥性HIV感染病患之臨床試驗協議
View More
UBI集團訊息
18112019
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria

They have received Investigational New Drug (IND) approval from the U.S. FDA to conduct a phase 1 clinical trial with a novel anti-IgE monoclonal antibody UB-221, in patients suffering from chronic spontaneous urticaria

UBI group

創新型IgE單株抗體UB-221
more
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria
View More
UBI集團訊息
18112019
聯生藥單株抗體新藥 UB-221 獲美國 FDA 核准在慢性自發性蕁麻疹患者進行臨床一期試驗

新型抗IgE單株抗體藥物 UB-221 已獲得美國FDA 核准在標準一線藥物H1 抗組織胺治療無效的慢性自發性蕁麻疹病患進行臨床一期試驗

UBI group

創新型IgE單株抗體UB-221
more
聯生藥單株抗體新藥 UB-221 獲美國 FDA 核准在慢性自發性蕁麻疹患者進行臨床一期試驗
View More
UBI集團訊息
06102019
英國著名PharmaBoardRoom媒體記者、訪問聯生藥董事長暨科學長王長怡博士

王長怡乃UBI旗下子公司之一的聯合生物製藥（United BioPharma，UBP）董事長兼首席科學長，而UBP正是她所創立的UBI集團的其中一企業。

UBI group

王長怡博士
more
英國著名PharmaBoardRoom媒體記者、訪問聯生藥董事長暨科學長王長怡博士
View More
UBI集團訊息
06102019
愛滋病「每日用藥」治療模式，可能因一篇台灣研究而改變

UB-421抗體不僅阻止愛滋病毒感染新細胞，它似乎也調整了受試者的免疫細胞，使他們能更容易地擊退病毒。

UBI group

愛滋病治療單株抗體UB-421
more
愛滋病「每日用藥」治療模式，可能因一篇台灣研究而改變
View More
UBI集團訊息
20072019
A vaccine for Alzheimer’s is on the verge of becoming a reality

Now, a mother and daughter team think they have finally found a solution – a vaccine that could inoculate potential sufferers

UBI group

UBITh®設計型疫苗

王長怡博士

阿茲海默症治療型疫苗UB-311
more
A vaccine for Alzheimer’s is on the verge of becoming a reality
View More
UBI集團訊息
19072019
Is an Alzheimer’s Cure on the Horizon?

THE FIELD IS LITTERED WITH FAILURES, UNLESS YOU CONSIDER FAILURES LEARNING.– MEI MEI HU

UBI group

UBITh®設計型疫苗

阿茲海默症治療型疫苗UB-311
more
Is an Alzheimer’s Cure on the Horizon?
View More
UBI集團訊息
11062019
United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients

Investigational New Drug (IND) approval from the U.S. FDA to conduct a phase 2 clinical trial with UB-621 monoclonal antibody for recurrent genital infection

UBI group

抗單純皰疹病毒(HSV)單株抗體UB-621
more
United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients
View More
UBI集團訊息
11062019
聯生藥治療單純皰疹病毒抗體新藥UB-621獲美國FDA核准執行臨床2期復發型生殖器皰疹試驗

抗皰疹病毒單株抗體藥物UB-621已獲得美國FDA批准在由HSV-2感染所引起之復發型生殖器皰疹患者族群上進行臨床第2期試驗

UBI group

抗單純皰疹病毒(HSV)單株抗體UB-621
more
聯生藥治療單純皰疹病毒抗體新藥UB-621獲美國FDA核准執行臨床2期復發型生殖器皰疹試驗
View More
UBI集團訊息
21052019
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection

A Multicenter, Single-Arm, 24-Week Study of UB-421 in Combination with Optimized Background Therapy (OBT) Regimen in Patients with Multi-Drug Resistant (MDR) HIV-1 Infection.

UBI group

愛滋病治療單株抗體UB-421
more
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
View More
UBI集團訊息
15052019
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients

IND approval from China NMPA to conduct a multi-nation, multi-center phase 3 clinical trial with UB-421 substitution monotherapy

UBI group

愛滋病治療單株抗體UB-421
more
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
View More
UBI集團訊息
15052019
聯生藥治療愛滋病抗體新藥UB-421獲中國國家藥品監督管理局核准多國多中心臨床3期試驗

治療愛滋病單株抗體新藥UB-421規劃在台灣、泰國與中國三個地區執行之多國多中心臨床3期試驗

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥治療愛滋病抗體新藥UB-421獲中國國家藥品監督管理局核准多國多中心臨床3期試驗